Navigation Links
Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results

SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that the company will report financial results for the quarter ended September 30, 2007, before the opening of trading on Wednesday, October 31, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Wednesday, October 31. The call is open on a listen-only basis to any interested parties. The company will provide details on independent and partnered development programs in the conference call and webcast.

To listen to the conference call, dial in approximately ten minutes before the scheduled call to (888) 600-4883, or (913) 312-6683 for international participants, and reference confirmation code 1036247. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter replay passcode 1036247. The call also will be available live and archived through the events page at

Invited analysts and institutional investors may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contacts: Investors: Media:

Alan R. Engbring Susan Neath

Vical Incorporated Porter Novelli Life Sciences

(858) 646-1127 (619) 849-6007


SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
(Date:11/23/2015)... VA (PRWEB) , ... November 23, 2015 , ... Noblis, ... McCarthy , former Director, Plans and Programs, National Geospatial Intelligence Agency (NGA), has joined ... us with an incredibly distinguished career in the intelligence community and the private sector,” ...
(Date:11/23/2015)... , November 23, 2015 biochar ... million in 2015, and it is expected to grow ... The factors driving the growth of the global market ... sequestration property of biochar, increased government initiatives and stringent ... initiatives and stringent environment regulations are the key drivers ...
(Date:11/23/2015)... Fla. , Nov. 23, 2015  Oxis ... Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: ... of Minnesota Masonic Cancer Center received notification from ... they can proceed with their planned combination Phase ... worldwide exclusive rights to develop and commercialize OXS-1550, ...
(Date:11/23/2015)... 2015 ) ... Global Molecular Diagnostics Market: Latest Instrumentation and ... to their offering.  --> ... "2016 Global Molecular Diagnostics Market: Latest Instrumentation ...  report to their offering.  --> ...
Breaking Biology Technology:
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
Breaking Biology News(10 mins):